|
| 37433103 | Standardized Definitions for Efficacy End Points in Neoadjuvant Breast Cancer Clinical Trials: NeoSTEEP. | J Clin Oncol | 2023 |
| 37733800 | Differential Benefit of Metronomic Chemotherapy Among Triple-Negative Breast Cancer Subtypes Treated in the IBCSG Trial 22-00. | | 2023 |
| 37683978 | Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023. | Ann Oncol | 2023 |
| 36521078 | Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials. | J Clin Oncol | 2023 |
| 37268625 | Clinical outcomes of de novo metastatic HER2-positive inflammatory breast cancer. | NPJ Breast Cancer | 2023 |
| 36493334 | Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT. | J Clin Oncol | 2023 |
| 37391304 | Re: Matthew S. Ernst, Vishal Navani, J. Connor Wells, et al. Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Groups in Contemporary First-line Combination Therapies for Metastatic Renal Cell Carcinoma. Eur Urol. 2 | | 2023 |
| 37440239 | Efficacy of Metronomic Oral Vinorelbine, Cyclophosphamide, and Capecitabine vs Weekly Intravenous Paclitaxel in Patients With Estrogen Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: Final Results From the Phase 2 METEORA-II Randomized Clinica | | 2023 |
| 35012846 | Effect of dose reductions on clinical outcomes, or of outcomes on dose reductions? | Breast | 2022 |
| 36175037 | Maximizing the value of phase III trials in immuno-oncology: A checklist from the Society for Immunotherapy of Cancer (SITC). | J Immunother Cancer | 2022 |
| 35380717 | Surrogacy Beyond Prognosis: The Importance of "Trial-Level" Surrogacy. | Oncologist | 2022 |
| 36210737 | Incidence, characteristics, and management of central nervous system metastases in patients with inflammatory breast cancer. | Cancer | 2022 |
| 35923923 | Early on-treatment transcriptional profiling as a tool for improving pathological response prediction in HER2-positive inflammatory breast cancer. | Ther Adv Med Oncol | 2022 |
| 36116830 | HER2-low inflammatory breast cancer: Clinicopathologic features and prognostic implications. | Eur J Cancer | 2022 |
| 36115609 | Reply to the Letter to the Editor 'Risk-adapted modulation through de-intensification of cancer treatments: an ESMO classification' by Hannoun-Levi et al. | Ann Oncol | 2022 |
| 35465733 | A phase III trial of alpelisib + trastuzumab ± fulvestrant versus trastuzumab + chemotherapy in HER2+ <i>PIK3CA</i>-mutated breast cancer. | Future Oncol | 2022 |
| 34855329 | Sensitivity of treatment-free survival to subgroup analyses in patients with advanced melanoma treated with immune checkpoint inhibitors. | Melanoma Research | 2022 |
| 35172272 | Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant. | Eur J Cancer | 2022 |
| 34433304 | Prospective Multicenter Comparison of Open and Robotic Radical Prostatectomy: The PROST-QA/RP2 Consortium. | J Urol | 2022 |
| 34836764 | Accelerating progress to innovation for patients: Trial design and risk stratification. | Breast | 2022 |
| 34475143 | Prepectoral versus subpectoral implant-based breast reconstruction after skin-sparing mastectomy or nipple-sparing mastectomy (OPBC-02/ PREPEC): a pragmatic, multicentre, randomised, superiority trial. | BMJ Open | 2021 |
| 33585999 | Phase I study of JAK1/2 inhibitor ruxolitinib with weekly paclitaxel for the treatment of HER2-negative metastatic breast cancer. | Cancer Chemother Pharmacol | 2021 |
| 34117261 | Circulating tumor cell number and endocrine therapy index in ER positive metastatic breast cancer patients. | npj Breast Cancer | 2021 |
| 34149037 | Dermal Lymphatic Invasion, Survival, and Time to Recurrence or Progression in Inflammatory Breast Cancer. | American Journal of Clinical Oncology: Cancer Clinical Trials | 2021 |
| 33991601 | Bringing safe and effective therapies to premenopausal women with breast cancer: efforts to broaden eligibility criteria. | Ann Oncol | 2021 |
| 33507815 | Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline. | J Clin Oncol | 2021 |
| 34312215 | A Grant-Based Experiment to Train Clinical Investigators: The AACR/ASCO Methods in Clinical Cancer Research Workshop. | Clin Cancer Res | 2021 |
| 33082214 | Genomic Aberrations and Late Recurrence in Postmenopausal Women with Hormone Receptor-positive Early Breast Cancer: Results from the SOLE Trial. | Clin Cancer Res | 2021 |
| 33290610 | Clinical behavior of recurrent hormone receptor-positive breast cancer by adjuvant endocrine therapy within the Breast International Group 1-98 clinical trial. | Cancer | 2021 |
| 33159633 | Cumulative incidence of cardiovascular events under tamoxifen and letrozole alone and in sequence: a report from the BIG 1-98 trial. | Breast Cancer Research and Treatment | 2021 |
| 34799400 | Treatment-free survival over extended follow-up of patients with advanced melanoma treated with immune checkpoint inhibitors in CheckMate 067. | Journal for ImmunoTherapy of Cancer | 2021 |
| 34759043 | Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial. | Clin Cancer Res | 2021 |
| 31448540 | Patterns of breast reconstruction in patients diagnosed with inflammatory breast cancer: The Dana-Farber Cancer Institute's Inflammatory Breast Cancer Program experience. | Breast Journal | 2020 |
| 32025567 | DNA methylation markers predict recurrence-free interval in triple-negative breast cancer. | NPJ Breast Cancer | 2020 |
| 31949268 | Correction: Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial. | Br J Cancer | 2020 |
| 31618131 | Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFT. | Journal of Clinical Oncology | 2020 |
| 31992108 | Clinical and economic outcomes of treatment sequences for intermediate- to poor-risk advanced renal cell carcinoma. | Immunotherapy | 2020 |
| 32274665 | Treatment-induced symptoms, depression and age as predictors of sexual problems in premenopausal women with early breast cancer receiving adjuvant endocrine therapy. | Breast Cancer Research and Treatment | 2020 |
| 32535486 | Estimation of historical control rate for a single arm de-escalation study - Application to the POSITIVE trial. | Breast | 2020 |
| 32943461 | Dual Blockade of c-MET and the Androgen Receptor in Metastatic Castration-resistant Prostate Cancer: A Phase I Study of Concurrent Enzalutamide and Crizotinib. | Clin Cancer Res | 2020 |
| 32723153 | DNA derived from archival tumor specimens can be used for germline pharmacogenetic analyses. | Pharmacogenomics | 2020 |
| 33052755 | Road Map to Safe and Well-Designed De-escalation Trials of Systemic Adjuvant Therapy for Solid Tumors. | J Clin Oncol | 2020 |
| 32552276 | Event-Free Survival, a Prostate-Specific Antigen-Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation. | J Clin Oncol | 2020 |
| 30933323 | Prevalence of germline variants in inflammatory breast cancer. | Cancer | 2019 |
| 31839154 | Risk stratification according to stage and pathology. | Breast | 2019 |
| 32337479 | Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 1: Late Recurrence: Current Understanding, Clinical Considerations. | JNCI Cancer Spectr | 2019 |
| 32337480 | Independent Validation of EarlyR Gene Signature in BIG 1-98: A Randomized, Double-Blind, Phase III Trial Comparing Letrozole and Tamoxifen as Adjuvant Endocrine Therapy for Postmenopausal Women With Hormone Receptor-Positive, Early Breast Cancer. | JNCI Cancer Spectrum | 2019 |
| 32337478 | Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 2: Approaches to Predict and Identify Late Recurrence, Research Directions. | JNCI Cancer Spectr | 2019 |
| 30171067 | Prognostic Value of the Progesterone Receptor by Subtype in Patients with Estrogen Receptor-Positive, HER-2 Negative Breast Cancer. | Oncologist | 2019 |
| 30589600 | Neoadjuvant Degarelix Versus Triptorelin in Premenopausal Patients Who Receive Letrozole for Locally Advanced Endocrine-Responsive Breast Cancer: A Randomized Phase II Trial. | Journal of Clinical Oncology | 2019 |